27 – 29 February 2020
Dubai World Trade Centre
MSD also known as Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co., Inc.,Whitehouse Station, NJ, USA) is a global research-driven pharmaceutical companydedicated to putting patients first. Established in 1891, MSD discovers, develops,manufactures and markets vaccines and medicines to address unmet medical needs.MSD has been present for over than 30 years in the GULF region. MSD GULF operatesthroughout offices based in the UAE, Kuwait, Bahrain, Qatar & Oman and ranksamongst the leading pharmaceutical companies throughout the GULF region. Throughits local distributors, MSD GULF provides innovative medications in several diseaseentities. These include products for Anti- Infectives, Cardiovascular, Asthma & Allergy,Diabetes, HCV, HIV, Pain & Inflammation, Osteoporosis, Oncology, Fertility,Ophthalmic, and Anesthesia in addition to several specialized Vaccines.
Diabetes is a lifelong challenge for people living with it.
That is why Lilly Diabetes provides a wide range of therapies connected with consistent support that allow care to be tailored as needs change.
We know that even with the best of medicines, it can be hard for people with diabetes to reach and stay at goal. Since we introduced the first commercially available insulin in 1923, the needs of people with diabetes have continually inspired us to innovate and introduce pathways to better outcomes.
We believe that when it comes to helping people achieve those outcomes, efficacy and safety are critical. We also understand that simplicity and ease of use are just as important.
For a person with diabetes, achieving a goal can be hard. Understanding and taking a medicine should not be.
Founded in Darmstadt, Germany, in 1668 by Friedrich Jacob Merck, we are the world's oldest pharmaceutical and chemical company. Today, the Merck family remains the majority owner of the company. Over the course of nearly 350 years, we have become a truly global company.
Our approximately 50,000 people work in 66 countries and are united by their passion for new ideas, the possibilities of technology, and the potential to make a difference in the world.
In healthcare we help to create, improve and prolong life - continuously working to make a lasting difference to patients' lives. Our portfolio includes medicines to treat cancer, multiple sclerosis, infertility, growth disorders, cardiovascular diseases, diabetes and thyroid disorders. We develop high-quality products that protect every member of your family so that they can enjoy healthier, happier lives every day We are known as Merck internationally. In the United States and Canada we operate as EMD Serono in the Biopharma business, as MilliporeSigma in the Life Science business, and as EMD Performance Materials in the materials business.
Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative "Making More Health" while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.
In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information please visit www.boehringer-ingelheim.com
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
For Novartis multimedia content, please visit www.novartis.com/news/media-library. For questions about the site or required registration, please contact: email@example.com
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries.
NN Story: Behind the Novo Nordisk we know today lies an exciting story that goes back 90 years. It began with the two small Danish companies Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium founded in 1923 and 1925, respectively. The two companies started the production of the revolutionary new drug insulin that had just been discovered by two Canadian scientists. A 1935 export advertisement for insulin Novo
Building on the past - looking to the future
Since the earliest days, both Nordisk and Novo had focus on the development of products to benefit people with diabetes. Competing intensely with one another, the companies developed into two of the best in their field. When at last they decided to merge in 1989, they created Novo Nordisk. A company that has been expanding rapidly ever since with leading positions within diabetes care, haemophilia care, growth hormone therapy and hormone replacement therapy.
Today the Novo Nordisk Way shows responsibility to patients, employees, communities and investors. We will in the future continue to build on the legacy left by the founders of Novo Nordisk and do whatever it takes to change diabetes. Our history tells us it can be done.
At Sanofi Diabetes, our priorities are focused on the needs of people with diabetes around the world. With a century of experience in this area, we strive to help people manage the complex challenge of diabetes by delivering a range of innovative, personalized solutions integrated across diagnostics, therapies, devices and services. Because we understand the daily impact of diabetes and our patients' aspirations, we know how to improve their quality of life. We want people to live 'beyond' diabetes, to achieve aspirations and to make the most of everyday!Our principal medicinal products in the field of diabetes are: Lantus® (insulin glargine), a long-acting human insulin analogue. Lantus® is available is more than 120 countries worldwide. Apidra® (insulin glulisine) a rapid-acting human insulin analogue. Lyxumia® (lixisenatide) is a once-daily prandial GLP-1 receptor agonist. Amaryl® (glimepiride), a sulfonylurea-class hypoglycemic. Furthermore, other diabetes treatments are currently in clinical development.
Servier is an independent French pharmaceutical research company. Its development is based on the continuous pursuit of innovation in the therapeutic areas of cardiovascular-, metabolic-, neurologic-, psychiatric-, bone- and joint diseases as well as cancer.
In 2014, the company recorded a turnover of 4 billion euros.
92% of Servier drugs are consumed outside of France.
25% of turnover from Servier drugs were reinvested in Research and Development in 2014.
With a strong international presence in 146 countries, Servier employs more than 21 400 people worldwide.
More information is available at: www.servier.com
Servier Communication Department:
Tel: +33 1 5572 6037
Janssen is one of the world's leading research-based pharmaceutical companies, with operations throughout the world. The name Janssen refers to Dr. Paul Janssen who started with pharmaceutical research in Belgium more than half a century ago.Janssen joined the Johnson & Johnson Family of Companies in 1961.
The Janssen Pharmaceutical Companies of Johnson & Johnson currently employ over 40,000 people, across five continents. At Janssen, we are driven by our commitment to patients to solve the most important unmet medical needs of our time. We develop innovative products, services and healthcare solutions in five important therapeutic areas: oncology, immunology, neuroscience, infectious diseases & vaccines and cardiovascular & metabolic diseases.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its manufacturing expertise to strive for solutions dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery,early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.
Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). We are also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. We operate in more than 100 countries and our innovative medicines are used by millions of patients worldwide. We want to be valued as a source of great medicines and trusted as a company that delivers business success responsibly. We are committed to operating with integrity and high ethical standards across all our activities. We push the boundaries of science to deliver life-changing medicines.
Lifescan is one of the world's leading providers of blood glucose monitoring systems. The OneTouch® portfolio of products and services has become a brand recommended by diabetes health professionals. The OneTouch® range of products is designed to meet the diverse needs of patients to help them better manage their diabetes.
Established in 2016 through the acquisition of Bayer Diabetes Care by Panasonic Healthcare Holdings, Ascensia Diabetes Care is a global company dedicated to improving the lives of people with diabetes and helping empower them to take charge of their health.
We are determined to continue developing our line of products, beyond our current CONTOURTM portfolio of meters, so that Ascensia Diabetes Care is the recognized world leader in delivering convenient, easy-to-useblood glucose monitoring systems and testing supplies. We collaborate closely with healthcare professionals and other partners to ensure our products meet the high standards of accuracy to help people with diabetes manage their condition, regardless of type of diabetes, stage ofdisease or frequency of testing required.
For more than 70 years, continuous research has allowed our diabetes care team to lead the way in blood glucose monitoring systems. These have been developed specifically to meet the needs of patients, and, along the way, we have introduced many firsts. We are proud of our heritage as a leading provider of solutions for diabetes care.We will continue to build on the legacy of our longstanding commitment to diabetes.
For further information please visit the Ascensia Diabetes Care website at: www.ascensia.com
PicSolution is a trademark of Artsana, leading Italian company in healthcare and baby products. Its new diabetes portfolio includes the wide InsupenExtr3mepen needles range featuring a special extra comfort needle geometry, High Flow Thin Wall33Gx4mm and 32Gx4mm pen needles and the ReVita/ReDermaintensive treatment foot care range (sanitizer, lotion and cream plus anti-flaking socks). Insumed syringes, Digitestlancing devices and lancets plus patient's accessories complete the assortment.
We develop, manufacture and market a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region and Europe. We are also a leading licensing partner in the MENA region. Our operations span over 50 countries and are conducted through three business segments; Branded, Injectables and Generics.
Our aim is to provide patients with better access to high-quality, affordable medicines in key therapeutic areas. Through organic growth and strategic acquisitions, we will continue to develop the business and maintain the high standards of ethics and responsibility that are central to the way we operate.
BD Medical-Diabetes care is a leading global medical technology company that develop, manufacture & sell medical devices instrument system & reagent. The company is dedicated to improve people's health throughout the world. BD is focusing on improving drug delivering, enhancing the quality & the speed of diagnosing infectious disease and cancer & advancing research, discovery & production of new drugs & vaccines.
As a global leader in diabetes care, Abbott is constantly working to deliver the highest quality products and unwavering support to our customers. Consistent and accurate glucose monitoring is the foundation of any diabetes management plan so we're committed to continuous improvement in the way patients and professionals measure, track and analyze glucose levels.
PEOPLE ACROSS THE WORLD COUNT. On the freestyle family of glucose monitoring systems to help them manage their diabetes. HEALTHCARE PROFESSIONALS Depend on Abbott to provide them with state of the art tools to help them care for their patients with diabetes.
Julphar is the largest generic pharmaceutical manufacturer in MENA. For over thirty years, we have been providing high quality, affordable medicines to families across the region. We operate thirteen internationally accredited facilities in the UAE and others located in Ethiopia, Bangladesh and KSA. We maintain a large and diverse range of medicines targeting major therapeutic segments, inclusive of biotechnology. Our strong network ensures distribution to over 40 countries worldwide.
ISO 9001:2008 and OHSAS 18001:2007 certified company Representing more than 40 leading manufacturers including Philips Health Care, Elekta, Teleflex, Hudson, Kubtec, Belmont Instruments, Acumed, Dysis, IMT Medical, Cardiac Science, MMPL, COCOON, Accuro, MGC Diagnostics, Medispec, Stiegelmeyer, Mindray, Dilon, DTF Medical, Diplomat Dental, ARDO and Evia Medical Technologies etc.
Dedicated Healthcare Products & Solutions Provider.
Established in 2004, Bridgeway Medical is a young and fast growing company led by a team with many years of experience in serving hospitals in Middle East and India. Bridgeway works closely with clinicians and other healthcare professionals to develop its products and provide solutions for optimum efficiency and patient care.
Bridgeway distributes a range of medical and rehabilitation products in UAE, Qatar and India. Bridgeway products include Rehabilitation Products, Homecare, Assisted Living aids, Specialized Seating Systems for children and single-use devices for Anaesthesia and a comprehensive range of Sterile Equipment Drapes, together with a number of Essential Surgical Accessories. Bridgeway also distribute Wound Care, Burn Care and Diabetic care products.
For Sponsorship and Exhibition inquiries, please contact firstname.lastname@example.org
Emirates Diabetes & Endocrine Congress (EDEC) is organized by Emirates Diabetes Society. EDEC is the region's premier platform to update attendees on the recent advances in the ever-changing field of diabetes and endocrine diseases.
|MCI Middle East |
United Arab Emirates
Tel: +971 4 311 6300
Fax: +971 4 311 6301